PlaqueTec Appoints CEO
This article was originally published in Scrip
PlaqueTec, Ltd., a company focused on developing biomarker based therapies for coronary artery disease, has appointed Dr. Tim Brears CEO. Previously Brears was CEO of a company he founded in 2002, Xention Limited, which develops drugs for atrial fibrillation. Prior to this, Brears was CEO of a gene-regulation company, Gendaq Limited (acquired by Sangamo Biosciences).